ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1781

Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cyclophosphamide, Lupus nephritis, meta-analysis, mycophenolate mofetil and tacrolimus

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative glomerulonephritis (WHO class III and IV). However, their benefits are outweighed by the significant drug-related adverse effects, such as an increased risk of serious infections and ovarian toxicity. Thus, other immunosuppressive drugs have been used for induction treatment of lupus nephritis, such as mycophenolate mofetil (MMF), and tacrolimus. However, evidence from a small number randomized controlled trials (RCT) comparing the relative efficacy and safety of tacrolimus or MMF with CYC, as induction agents in lupus nephritis, has been inconclusive, mainly because of their small sample sizes. This study aimed to assess the relative efficacy and safety of tacrolimus, MMF, and CYC as induction therapy for lupus nephritis.

Methods: RCTs examining the efficacy and safety of tacrolimus, MMF, and CYC for induction therapy in patients with lupus nephritis were included. We performed a Bayesian random-effects network meta-analysis to combine direct and indirect evidence from the RCTs.

Results: Nine RCTs including 972 patients met the inclusion criteria. There pairwise comparisons were performed, including 11 direct comparisons. Tacrolimus showed a significantly higher overall response rate (complete remission plus partial remission) than CYC (OR 2.35, 95% credible interval (CrI) 1.03–5.45), and was more efficacious than MMF (OR 1.60, 95% CrI 0.70–3.57). MMF was superior to CYC in terms of overall response (OR 1.45, 95% CrI 0.96–2.42). Ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that tacrolimus had the highest probability of being the best treatment for achieving the overall response (SUCRA = 0.9321), followed by MMF (SUCRA = 0.5385), and CYC (SUCRA = 0.0294). In terms of safety, tacrolimus showed the highest probability of decreasing the risk of serious infections (SUCRA = 0.9253), followed by MMF (SUCRA = 0.4027), and CYC (SUCRA = 0.1720).

Conclusion: Tacrolimus was the most efficacious induction treatment for patients with lupus nephritis, and had the highest probability of decreasing the risk of serious infections. Higher remission rates combined with a more favorable safety profile suggest that MMF is superior to CYC as induction treatment in these patients.


Disclosure: Y. H. Lee, None; G. G. Song, None.

To cite this abstract in AMA style:

Lee YH, Song GG. Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/comparative-efficacy-and-safety-of-tacrolimus-mycophenolate-mofetil-and-cyclophosphamide-as-induction-therapy-for-lupus-nephritis-a-bayesian-network-meta-analysis-of-randomized-controlled-trials/. Accessed February 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-efficacy-and-safety-of-tacrolimus-mycophenolate-mofetil-and-cyclophosphamide-as-induction-therapy-for-lupus-nephritis-a-bayesian-network-meta-analysis-of-randomized-controlled-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.